Patents by Inventor Michael Joseph Surace

Michael Joseph Surace has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1
    Publication number: 20250129159
    Abstract: Provided herein are methods for treating cancer using molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Also included are molecules having an antigen binding fragment that immunospecifically bind to BTN1A1 dimers, such as anti-BTN1A1 dimer antibodies. Also provided are methods for treating anti-PD-1 therapy or anti-PD-L1 therapy resistant or refractory cancers.
    Type: Application
    Filed: December 20, 2024
    Publication date: April 24, 2025
    Inventors: Stephen Sunghan Yoo, Yong-Sik Bong, Kyu Lee Han, Michael Joseph Surace
  • Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
    Patent number: 12215151
    Abstract: Provided herein are methods for treating cancer using molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Also included are molecules having an antigen binding fragment that immunospecifically bind to BTN1A1 dimers, such as anti-BTN1A1 dimer antibodies. Also provided are methods for treating anti-PD-1 therapy or anti-PD-L1 therapy resistant or refractory cancers.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: February 4, 2025
    Assignee: STCUBE & CO., INC.
    Inventors: Stephen Sunghan Yoo, Yong-Sik Bong, Kyu Lee Han, Michael Joseph Surace
  • ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1 AND THE THERAPEUTIC USES THEREOF
    Publication number: 20240343797
    Abstract: Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.
    Type: Application
    Filed: April 3, 2024
    Publication date: October 17, 2024
    Inventors: Stephen Sunghan Yoo, Michael Joseph Surace, Steven Hsesheng Lin, Amrish Sharma
  • Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
    Patent number: 11970534
    Abstract: Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: April 30, 2024
    Assignees: STCUBE & CO., INC., Board of Regents, The University of Texas System
    Inventors: Stephen Sunghan Yoo, Michael Joseph Surace, Steven Hsesheng Lin, Amrish Sharma
  • ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1 AND THE THERAPEUTIC USES THEREOF
    Publication number: 20210147537
    Abstract: Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.
    Type: Application
    Filed: November 24, 2020
    Publication date: May 20, 2021
    Inventors: Stephen Sunghan Yoo, Michael Joseph Surace, Steven Hsesheng Lin, Amrish Sharma
  • Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
    Patent number: 10875920
    Abstract: Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 29, 2020
    Assignees: STCUBE & CO., INC., Board of Regents, The University of Texas System
    Inventors: Stephen Sunghan Yoo, Michael Joseph Surace, Steven Hsesheng Lin, Amrish Sharma
  • METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1
    Publication number: 20200131266
    Abstract: Provided herein are methods for treating cancer using molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Also included are molecules having an antigen binding fragment that immunospecifically bind to BTN1A1 dimers, such as anti-BTN1A1 dimer antibodies. Also provided are methods for treating anti-PD-1 therapy or anti-PD-L1 therapy resistant or refractory cancers.
    Type: Application
    Filed: May 30, 2018
    Publication date: April 30, 2020
    Inventors: Stephen Sunghan Yoo, Yong-Sik Bong, Kyu Lee Han, Michael Joseph Surace
  • ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1 AND THE THERAPEUTIC USES THEREOF
    Publication number: 20180355035
    Abstract: Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.
    Type: Application
    Filed: December 1, 2016
    Publication date: December 13, 2018
    Inventors: Stephen Sunghan Yoo, Michael Joseph Surace, Steven Hsesheng Lin, Amrish Sharma